Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism

Circulation

Volumn 109, Issue 23, 2004, Pages 2857-2861

  Nishizaka, Mari K ^a,b   Zaman, M Amin ^a   Green, Sharon A ^a   Renfroe, Kerry Y ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b 115 CHSB 19th ^*  (United States)

Author keywords

Aldosterone; Hypertension; Renin; Ultrasonics; Vasodilation

Indexed keywords

ALDOSTERONE; ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE; SPIRONOLACTONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTERY COMPLIANCE; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BODY MASS; BRACHIAL ARTERY; FEMALE; FOREARM BLOOD FLOW; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPEREMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ULTRASOUND; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADULT; ALDOSTERONE; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HEMORHEOLOGY; HUMANS; HYPERALDOSTERONISM; HYPEREMIA; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN; SODIUM; VASODILATION;

EID: 2942685646     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000129307.26791.8E     Document Type: Article

References (24)

1. Ikeda U, Kanbe T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol. 1995;290:69-73.
2. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. J Am Coll Cardiol. 2002;39:351-358.
3. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105: 2212-2216.
4. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10: 1326-1334.
5. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients, Eur Heart J. 1998;19:1371-1376.
6. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
7. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
8. Iiyama K, Nagano M, Yo Y, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J. 1996;132:779-782.
9. Celemajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
10. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997;30:325-333.
11. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 2003;41:661-665.
12. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
13. Young WF Jr. Minireview: primary aldosteronism: changing concepts in diagnosis and treatment. Endocrinology. 2003;144:2208-2213.
14. Thakkar RB, Oparil S. Primary aldosteronism: a practical approach to diagnosis and treatment. J Clin Hypertens. 2001;3:189-195.
15. Corretti MC, Anderson TJ, Benjamin EJ, et al, Guidelines for the ultrasound assessment of endothelial-dependent vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257-265.
16. Herrington DM, Fan L, Drum F, et al. Brachial flow-mediated vasodilatior responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter. J Cardiovasc Risk. 2001;8:319-328.
17. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;19:925-930.
18. RALES Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
19. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
20. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
21. Ghiadoni L, Huang Y, Magagna A, et al. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens. 2001;19:547-551.
22. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-1286.
23. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension. 1999;33:575-580.
24. Gokce N, Keaney JF, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769-1775.